FY26 Annual Report

Key points

• Net loss after tax of $428,603 compared to $1,463,310 in FY2025
• Company exited voluntary administration in May 2025
• Sold geneType, AffinityDNA, and EasyDNA businesses in FY25
• Cash balance at end of FY26 was $10,247
• Company's securities suspended from ASX trading since October 2024

Full summary

Genetic Technologies Ltd reported a net loss of $428,603 for the financial year ended 30 June 2026, compared to a loss of $1,463,310 in FY25. The company exited voluntary administration in May 2025 and has since sold its geneType, AffinityDNA, and EasyDNA businesses. As a result, the company did not conduct any trading operations during FY26. The company's cash balance at the end of FY26 was $10,247. Its securities have been suspended from trading on the ASX since October 2024 and remain suspended as of the report date.